Agilent Technologies Inc Stock Price, News & Analysis

Agilent Technologies (NYSE: A) has launched the SureSelect Human All Exon V8, enhancing exome sequencing capabilities for genomics research. This new design covers key protein coding regions along with hard-to-capture exons, offering options for routine, clinical, and translational research. The panel spans a 35.1 Mb target region, ensuring outstanding enrichment performance and cost-effective sequencing. Kevin Meldrum highlighted its significance in exome sequencing's growth, further supported by automation on the Bravo platform for efficient laboratory operations.

Agilent Technologies Inc. (NYSE: A) reported second-quarter revenue of $1.525 billion, marking a 23% increase year-over-year and 19% growth on a core basis. GAAP net income rose to $216 million or 70 cents per share from $101 million or 32 cents a year prior. Non-GAAP net income reached $299 million or 97 cents per share, compared to $223 million or 71 cents last year. The company raised its fiscal 2021 revenue outlook to between $6.15 billion and $6.21 billion, with non-GAAP earnings guidance adjusted to $4.09 to $4.14 per share.

Agilent Technologies (NYSE: A) is set to participate in the Jefferies Virtual Healthcare Conference on June 1, 2021, at 2:00 p.m. (ET). Bob McMahon, Agilent's Chief Financial Officer, will represent the company during this event. Interested participants can access the webcast through the Investor Relations section of the Agilent website.

Agilent Technologies, Inc. (NYSE: A) has declared a quarterly dividend of 19.4 cents per share, payable on July 28, 2021, to shareholders on record as of July 6, 2021. The company's future dividend amounts are subject to approval by its board of directors. In fiscal year 2020, Agilent generated $5.34 billion in revenue and employs 16,400 people globally. The press release highlights the company's commitment to returning value to shareholders while noting potential risks associated with forward-looking statements regarding its dividend program.

Agilent Technologies Inc. (NYSE: A) will announce its second-quarter fiscal year 2021 financial results on May 25, 2021, after market close. A live webcast of the investor conference call will occur at 1:30 p.m. Pacific time on the same day. The webcast will be available for 90 days on Agilent's website. In fiscal year 2020, Agilent generated revenue of $5.34 billion and has a workforce of 16,400 globally. This event provides investors an insight into the company’s performance and future direction.

Agilent Technologies Inc. (NYSE: A) has achieved the Accountability, Consistency and Transparency (ACT) Label for its InfinityLab LC/MSD iQ and Ultivo Triple Quadrupole LC/MS systems from My Green Lab, enhancing its commitment to sustainability in scientific research.

As part of this initiative, Agilent aims to assist laboratories in reaching their sustainability goals, with 87% of lab managers recognizing its importance. Additionally, Agilent has launched a Plant a Tree program aimed at planting over 1,500 trees across multiple countries by September 2021.

Agilent Technologies, Inc. (NYSE: A) has successfully acquired Resolution Bioscience, enhancing its capabilities in next-generation sequencing (NGS)-based cancer diagnostics. This acquisition expands Agilent's precision oncology solutions, particularly in liquid biopsy-based diagnostics, positioning the company to meet growing market demands. Agilent's CEO, Mike McMullen, emphasized the strategic importance of this addition, which aims to broaden access to NGS-based testing globally. The deal potentially boosts growth in Agilent's diagnostics and genomics sectors.

Agilent Technologies (NYSE: A) awarded Octagon Therapeutics a Golden Ticket during a virtual event on March 24, enabling one scientist's lab bench space for a year at LabCentral. The competition featured three semi-finalists, and Octagon was chosen based on its innovative research approach to autoimmune diseases. Darlene Solomon of Agilent expressed enthusiasm for Octagon's potential, while Isaac Stoner of Octagon highlighted the critical role of Agilent's resources in developing new treatments. Agilent, a leader in life sciences and diagnostics, reported revenue of $5.34 billion in fiscal year 2020.